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In the global objective of developing better medicines for chil-
dren, a recurring question in the field of drug delivery remains: 
“from what age can solid oral dosage forms be developed and 
safely prescribed for children?” Solid formulations offer numer-
ous advantages over liquids, both from a pharmaceutical devel-
opment and end-user perspective. This includes superior taste 
masking opportunities, a requirement for fewer excipients, 
easy and complete dose delivery, and the capability to include 
functionalities such as modified-release systems. Conventional 
tablets and capsules have been the principal means of oral drug 
delivery for nearly a century, while the emergence of innovative 
multiparticulate, (oro-)dispersible, and mini-tablet technologies 
enables the same dosing flexibility and ease of ingestion that have 
traditionally heralded liquids as the “gold standard” in pediatrics.
Provision of a suitable dosage form is an important factor that 
governs the age appropriateness of pediatric formulations, yet 
there is little evidence to support their suitability and acceptability 
among this population. Furthermore, there are few data to dem-
onstrate how specific characteristics such as size and shape should 
be addressed to render these forms appropriate for children. Until 
recently, there has been little primary research addressing this 
issue, as well as a lack of important formulation information being 
published in pediatric trials and few studies addressing patient-
related outcomes such as formulation acceptance and adherence.1 
Nevertheless, research in this area is emerging, driven by legisla-
tive changes and evolving regulatory guidance.
REGULATORY DEVELOPMENTS
The requirement for an age-appropriate formulation is stipu-
lated in global legislation: the “Paediatric Regulation” in the 
European Union mandates a pediatric investigation plan 
describing “measures to adapt the formulation … to make its 
use more acceptable, easier, safer or more effective,” whereas 
under the US Pediatric Research Equity Act, pediatric assess-
ments should gather data “using appropriate formulations for 
each age group.” An initial reflection paper published by the 
European Medicines Agency (EMA) acknowledged the question 
of formulation suitability. While recognizing the inherent vari-
ability among children, as well as the influence of a multitude 
of patient- and disease-related factors, 6 years was proposed as 
the approximate age from which solid forms such as tablets and 
capsules could be taken.2 Despite some caution, particularly due 
to its insufficient evidence base, this reflection paper remained a 
strong point of reference and had a major impact on the evalu-
ation of early regulatory submissions.
This resource has been somewhat superseded by the recent 
draft publication of the much-anticipated EMA guideline, 
another important milestone in the area of pediatric formula-
tions.3 Benefiting from some emerging data, particularly in the 
case of multiparticulates and mini-tablets, a more comprehen-
sive approach was initially proposed, notably in the appraisal of 
acceptable tablet sizes as a function of age. Dosage form size is 
fundamental to a child’s ability to swallow, and it was proposed 
that, unless justified by appropriate studies or clinical evidence, 
the specific dimensions shown in Table 1 would be deemed 
appropriate for tablets.
Following release for public consultation, these proposals were 
criticized for lacking an adequate evidence base, despite the need 
for investigators to fully justify and support deviations with an 
appropriate level of corroboration. On the other hand, some 
commenters requested further definitive guidance, including 
provision of specific capsule size limits in relation to age.4 The 
Both researchers and practitioners have reached an influential period in the new era of developing pediatric medicines. 
Evolving regulatory reforms and guidance continue to serve as platforms steering research and development while 
distinctive opportunities and challenges in the field emerge. An advancing research need involves gaining a better 
understanding of end-user requirements and acceptability of formulations. This review considers solid oral forms to 
demonstrate the importance of such research to stakeholders in policy and practice.
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need for systematic and transparent regulatory evaluation is well 
established, and, understandably, developers seek to follow duly 
endorsed scientific advice. Herein lies the “catch-22”—regulators 
are unable to provide rigorous guidance in light of the well-
acknowledged paucity of evidence available, yet when propos-
ing formulation development strategies, investigators need to 
support their approach with the same.
Although stakeholders’ reservations toward this prescriptive 
guidance are justified, its logic-based approach is nevertheless a 
step in the right direction; it initiates discussion and highlights 
how formulation-related factors need to be considered alongside 
those of the intended population and therapeutic indication. 
Although this prohibitive level of detail has been removed from 
the next revision, “a more general requirement for justification 
by applicants” is still required.5 However, even a more communi-
cative approach that discusses the benefit–risk profile of the for-
mulation strategy still requires supporting evidence. Likewise, 
although the US Food and Drug Administration has given no 
specific direction regarding this issue, it is envisaged that sub-
stantiation of acceptability will similarly support regulatory eval-
uations in the United States. The need to understand how the 
interplay of population, disease, and formulation-related factors 
can affect children’s ability and willingness to accept formula-
tions is thus a pertinent research need.
Initiatives such as the Seventh Programme Framework in 
the European Union and National Institutes of Health pro-
gram announcements (e.g., PAR-11-301 to PAR-11-305) in 
the United States show government support toward pediatric 
formulation research, to help close the gap of the current catch-
22. Nonetheless, both the EU and US regulations are oriented 
toward interactions between regulatory authorities and usually 
pharmaceutical companies. For formulations developed in an 
academic setting, subsequent linkage with regulators is less 
defined, posing the risk that innovative formulations developed 
in an academic institution may never positively impact pediatric 
therapeutics, unless purchased by a manufacturer.
POLICY TO PRACTICE
In the era of evidence-based medicine, guidance toward choos-
ing the most suitable formulation is another important factor 
that would contribute to ensuring optimum therapeutics in 
children. Even the most efficacious drug therapies will be futile 
if not acceptable or adhered to by patients. Furthermore, the 
attitudes and choices of health-care providers strongly influence 
which formulations are administered to patients in clinical prac-
tice, and this is an important link yet to receive adequate consid-
eration. In the case of oral medicines, for example, the age from 
which children are prescribed solid forms over liquids is subject 
to the judgment and experience of the clinician. Assessing the 
perceptions of stakeholders at the bedside, including patients, 
caregivers, and health-care professionals, is an important area 
that needs to be addressed in order to ensure that evolving regu-
latory guidelines fully reflect pediatric medicines use in practice.
Currently, EMA guidance specifies the need to assess the 
acceptability of pediatric medicinal products as an integral part 
of pharmaceutical development studies, primarily with children 
themselves but also giving due consideration to the needs of 
caregivers.5 Clinical practitioners should be aware of this as an 
anticipated outcome measure in impending clinical studies. 
Assessing this aspect of therapeutics may be beneficial further, 
as incompatibility between the medicinal product and patient, 
or likewise the caregiver, could potentially affect adherence to 
treatment regimens and even patient retention in clinical trials.
METHODOLOGICAL CONSIDERATIONS
Investigators must duly consider and justify their methodologi-
cal approach toward evaluating this latent variable, including 
the means of assessment and outcome measures. Currently, few 
data exist in both typical and atypical populations, and small, 
nonrepresentative samples invariably lead to inconsistent and 
limited findings. In the case of swallowability, there is little con-
sensus regarding the relationship between dosage form geom-
etry and the influence of patient-related factors, including age, 
developmental capability (e.g., swallowing coordination), and 
prior experience. From a traditionalist view, considering solid 
forms for infants and toddlers would be implausible; however, 
the emergence of multiparticulate technologies reforms this. 
These formulations offer greater ease of swallowing and show 
potential for use from ~6 months of age, when infants start to 
accept semisolid foods. An emerging research issue is estab-
lishing the dose quantity (or volume) of multiparticulates that 
would be appropriate for different ages.
The validity and reliability of study designs are also important. 
Exploratory studies using placebos of these novel forms are valu-
able to show their proof-of-concept but may not be comparable 
to extended investigations with the intended clinical populations 
to indicate long-term acceptability. Furthermore, by agreeing to 
take part in such research, participants inherently have a posi-
tive attitude to the formulation being investigated, a bias that can 
threaten the validity of findings. Understanding reasons for dis-
sent and exploring perceptions of formulations overall would also 
be informative to help identify potential barriers to acceptance.
Furthermore, a lack of formulation-related problems reported 
during studies may not necessarily be a reliable indication of 
appropriateness or acceptability because it is well acknowledged 
that patients and caregivers often adopt pragmatic measures to 
administer medicines, including modification of dosage forms. 
Rather than solely relying on patient or carer self-reports, 
including an objective, researcher-observed measure might be 
Table 1  Suitable dimensions for tablets (width or length, 
whichever is longest), as initially proposed in the “EMA Guideline 
on Pharmaceutical Development of Medicines for Paediatric Use”
Age Acceptable tablet diameter
6 Months to <2 years None; multiparticulates (powders, 
granules, or pellets) acceptable
2–5 Years 3–5 mm (Small tablets)
6–11 Years 5–10 mm (Medium tablets)
12–18 Years 10–15 mm (Large tablets)
EMA, European Medicines Agency.
From ref. 3.
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preferable. Although the EMA states that adequate assurance of 
acceptability is “not to be understood as 100% acceptance” in the 
target population,5 a threshold from which formulations can be 
deemed acceptable is yet to be defined.
CONCLUSIONS
Determining end-user acceptability of pediatric medicines is 
a challenging and evolving research need for which a multi-
focal and multidisciplinary approach is needed. The EMA’s 
requirement to assess this aspect will have a positive impact 
on pediatric therapeutics. Aside from published literature evi-
dence, outcomes of any clinical studies could provide the vital 
evidence required to guide formulation development, although 
availability in a public domain is not guaranteed. An important 
objective of the EU regulation was to improve the availability of 
information on the use of medicines without subjecting children 
to unnecessary trials. In light of this, establishing an arena to 
share essential formulation information may be a pivotal step 
in the future of pediatric formulation development.
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